Listen Score
LS 45
Global Rank
TOP 1%

TIETOJA TÄSTÄ PODCASTISTA 🔗

Juontajat:
Päivitä taajuus:
every 8 days
Keskimääräinen äänen pituus:
16 minutes
Vierashaastattelut
Englanti
Yhdysvallat
212 jaksoa
vuodesta 4. huhtikuuta 2022
episodic

AUDIENCE OF THIS PODCAST 🔗

~88.07% of listeners are from United States.
🇺🇸
US
88.07%
🇵🇱
PL
8.94%
🇮🇳
IN
0.59%
🇦🇲
AM
0.44%
🇸🇾
SY
0.29%
🇦🇺
AU
0.29%
🇨🇦
CA
0.29%
🇹🇼
TW
0.14%
🇵🇭
PH
0.14%
🇮🇪
IE
0.14%
🇰🇷
KR
0.14%
🇪🇸
ES
0.14%
🇳🇿
NZ
0.14%
🇵🇰
PK
0.14%
Others
0.11%
* Data source: directly measured on Listen Notes. reaaliaikainen

VIIMEISIN JAKSO 🔗

We are providing 2026 update for our breast cancer episodes, today we cover an introduction on breast cancer screening, prevention. 

HAE EDELLISIÄ EPISODEJA

Hae kanavan Two Onc Docs vanhoja jaksoja.

EDELLISET JAKSOT

This week’s episode we are very excited to welcome back our special guest Dr. Hatim Husain, MD, a medical oncologist and physician-scientist at UC San Diego Moores Cancer Center, whose clinical and research expertise focuses on lung cancer and precision oncology. We further cover the topic of ctDNA…
This week’s episode we are very excited to welcome a special guest Dr. Hatim Husain, MD, a medical oncologist and physician-scientist at UC San Diego Moores Cancer Center, whose clinical and research expertise focuses on lung cancer and precision oncology. We cover the topic of liquid biopsies, ctD…
 This week's episode focuses on metastatic non-small cell lung cancer - the quickly growing and changing systemic therapy landscape, including traditional chemotherapy, immunotherapy, and targeted agents. Since our last recording the number of FDA-approved targeted drugs has  significantly exp…
This week's episode focuses on early-stage and locally advanced non-small cell lung cancer - staging, pathology, local and systemic therapy. Before we start, the usual caveat: the treatment landscape of NSCLC is changing FAST, which is exciting, but know that the boards run a few years behind.…
Today’s episode is focusing on what you need to know regarding myelodysplastic syndrome (MDS). This will include the high yield facts on risk factors, diagnostic work-up, staging and treatment of MDS, we were overdue do this this topic, last done in 2022.
This week’s episode will be focusing on syndromes of iron overload. We will go over all important details on hemochromatosis and other related diseases. We last covered this topic in 2023.
This week’s episode will be focusing on how to approach a newly diagnosed malignancy, biopsy, staging, patient considerations ect.
This week’s episode will be focusing on how to transition well into heme/onc fellowship including differences from residency, tips for surviving, wellness, resources & more.

DLBCL 2026 UPDATE

This week’s episode will be focusing on Diffuse Large B-Cell Lymphoma (DLBCL). We will go all the important details on this aggressive NHL which can be highly curable. We have some new changes since we last covered this topic in 2022 including a new category 1 option for advanced DLBCL
Vastuuvapautusilmoitus: Tälle sivulle upotettu podcast ja kuvitus ovat peräisin Sam and Karine:ltä, joka on sen omistajan omaisuutta, eikä se ole sidoksissa Listen Notes, Inc:n tukemaan.